Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

BACKGROUND: Gemcitabine (GEM) is the first-line chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress responsive transcription factor, is an important contributor to chemoresistance and po...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Juan, Xu, Hong-Xi, Cho, William Chi Shing, Cheuk, Wah, Li, Yang, Huang, Qiong-Hui, Yang, Wen, Xian, Yan-Fang, Lin, Zhi-Xiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908700/
https://www.ncbi.nlm.nih.gov/pubmed/35272669
http://dx.doi.org/10.1186/s13046-022-02270-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908700/
https://www.ncbi.nlm.nih.gov/pubmed/35272669
http://dx.doi.org/10.1186/s13046-022-02270-z

Ejemplares similares